The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants

Journal of Clinical Pharmacology

Volumn 51, Issue 2, 2011, Pages 237-242

  Song, Ivy ^a   Min, Sherene S ^a   Borland, Julie ^a   Lou, Yu ^a   Chen, Shuguang ^a   Patel, Parul ^a   Ishibashi, Toru ^b   Piscitelli, Stephen C ^a  

^a GLAXOSMITHKLINE   (United States)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

antiretroviral; HIV 1; integrase inhibitor; S GSK1349572

Indexed keywords

DARUNAVIR; DARUNAVIR PLUS RITONAVIR; GSK 1349572; INTEGRASE INHIBITOR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; RITONAVIR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NORMAL HUMAN;

ADOLESCENT; ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG COMBINATIONS; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PYRIMIDINONES; RITONAVIR; SULFONAMIDES; YOUNG ADULT;

EID: 79551709965     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010371113     Document Type: Article

References (12)

1. Markowitz M., Nguyen BY, Gotuzzo E., et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naïve patients with HIV-1 infection. J Acquir Immune Defic Syndr. 2009 ; 52: 350-356.
2. Zolopa AR, Lampiris H., Blick G., et al. The HIV integrase inhibitor elvitegravir has potent and durable activity in treatment-experienced patients with active optimized background therapy. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy ; September 17-20, 2007 ; Chicago, Illinois. Abstract H-714.
3. Lalezari J., Sloan L., DeJesus E., et al. Potent antiviral activity of S/GSK1349572, a next generation integrase inhibitor (INI), in INInaïve HIV-1-infected patients. Presented at: International AIDS Society 5th Conference on HIV Pathogenesis, Treatment, and Prevention ; July 19-22, 2009 ; Cape Town, South Africa.
4. Underwood M., Johns B., Sato A., Fujiwara T., Spreen W. S/ GSK1349572: a next generation integrase inhibitor with activity against integrase inhibitor resistant clinical isolates from patients experiencing virologic failure while on raltegravir therapy. Presented at: International AIDS Society 5th Conference on HIV Pathogenesis, Treatment, and Prevention ; July 19-22, 2009 ; Cape Town, South Africa.
5. Min S., Song I., Borland J., et al. Pharmacokinetics and safety in healthy subjects of S/GSK1349572, a next generation HIV integrase inhibitor in healthy volunteers. Antimicrob Agents Chemother. 2010 ; 54: 254-258.
6. Peng J., Pulido F., Causemaker S., et al. Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment. J Clin Pharmacol. 2006 ; 46: 265-274.
7. Sekar V., Lefebvre E., De Paepe E., et al. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. Antimicrob Agents Chemother. 2007 ; 51: 958-961.
8. Sekar V., Spinosa-Guzman S., De Paepe E., et al. Darunavir/ ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers. J Clin Pharmacol. 2008 ; 48: 60-65.
9. Sekar V., Lefebvre E., De Pauw M., Vangeneugden T., Hoetelmans R. Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers. Br J Clin Pharmacol. 2008 ; 66: 215-221.
10. van Heeswijk R., Bourbeau M., Campbell P., et al. Time-dependent interaction between lopinavir/ritonavir and fexofenadine. J Clin Pharmacol. 2006 ; 46: 758-767.
11. Song I., Chen S., Lou Y., et al. Pharmacokinetic and pharmacodynamic relationship of S/GSK1349572, a next generation integrase inhibitor, in HIV-1 infected patients. Presented at: International AIDS Society 5th Conference on HIV Pathogenesis, Treatment, and Prevention ; July 19-22, 2009 ; Cape Town, South Africa. Abstract WEPEB250.
12. Hsu A., Granneman GR, Bertz RJ Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet. 1998 ; 35: 275-291.